학술논문
Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT.
Document Type
Academic Journal
Author
Pagliuca S; Department of Hematology, Nancy University Hospital, Nancy, France; UMR 7365, IMoPA, Lorraine University, CNRS, Vandœuvre-lès-Nancy, France.; Schmid C; Department of Haematology and Oncology, Augsburg University Hospital and Medical Faculty Comprehensive Cancer Center, Bavarian Cancer Research Center, Augsburg, Germany.; Santoro N; Haematology Unit, Department of Oncology and Hematology, Santo Spirito Hospital, Pescara, Italy.; Simonetta F; Division of Haematology, Department of Oncology, Geneva University Hospitals, Geneva, Switzerland.; Battipaglia G; Haematology Department and Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.; Guillaume T; Division of Haematology, Nantes University Hospital, Nantes, France; INSERM U1232 CNRS, CRCINA, Nantes, France.; Greco R; Haematology and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Onida F; Haematology and BMT Unit, ASST Fatebenefratelli Sacco, University of Milan, Milan, Italy.; Sánchez-Ortega I; EBMT executive office, Barcelona, Spain.; Yakoub-Agha I; CHU de Lille, Université de Lille, INSERM U1286, Infinite, Lille, France.; Kuball J; Department of Haematology and Center for Translational Immunology, UMC Utrecht, Utrecht, Netherlands.; Hazenberg MD; Department of Haematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.; Ruggeri A; Haematology and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: ruggeri.annalisa@hsr.it.
Source
Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Subject
Language
English
Abstract
Since the early description of three patients with relapsed leukaemia after allogeneic haematopoietic cell transplantation (HCT) who obtained complete remission after donor lymphocyte infusions (DLIs), the added value of this procedure to induce or maintain graft-versus-leukaemia immunity has been undisputed. For more than 30 years, DLIs have become common practice as prophylactic, pre-emptive, or therapeutic immunotherapy. However, as with many aspects of allogeneic HCT, centres have developed their own routines and practices, and many questions related to the optimal applications and toxicity, or to the immunobiology of DLI induced tumour-immunity, remain. As a part of the Practice Harmonization and Guidelines Committee and the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation effort, a panel of experts with clinical and translational knowledge in transplantation immunology and cellular therapy met during a 2-day workshop in September, 2023, in Lille, France, and developed a set of consensus-based recommendations for the application of unmanipulated DLI after allogeneic HCT for haematological malignancies. Given the absence of prospective data in the majority of publications, these recommendations are mostly based on retrospective studies and expert consensus.
Competing Interests: Declaration of interests SP has received travel expenses or honoraria for participation in advisory boards, symposia, or other scientific events from Alexion, Novartis, Jazz Pharmaceutical, Therakos, OneLamda, and Sobi; and received research funding from Janssen Horizon. CS has received travel expenses or honoraria for participation in advisory boards, symposia, or other scientific events from Novartis, Jazz Pharmaceutical, Neovii, Janssen, and Kite Pharma. JK has received grants from Novartis, Miltenyi Biotech, and Gadeta; is a Gadeta shareholder; and holds patent licenses with Gadeta and Miltenyi Biotech. All other authors declare no competing interests.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Competing Interests: Declaration of interests SP has received travel expenses or honoraria for participation in advisory boards, symposia, or other scientific events from Alexion, Novartis, Jazz Pharmaceutical, Therakos, OneLamda, and Sobi; and received research funding from Janssen Horizon. CS has received travel expenses or honoraria for participation in advisory boards, symposia, or other scientific events from Novartis, Jazz Pharmaceutical, Neovii, Janssen, and Kite Pharma. JK has received grants from Novartis, Miltenyi Biotech, and Gadeta; is a Gadeta shareholder; and holds patent licenses with Gadeta and Miltenyi Biotech. All other authors declare no competing interests.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)